Table 2 Characteristics of studies of nebulised magnesium sulphate.
| Study | Location | Publication year | Total sample | Age range (years) | Sex %F:M | Asthma severity | Jadad Score | Outcome measure |
|---|---|---|---|---|---|---|---|---|
| Aggarwal | India | 2006 | 100 | 13–60 | 40:60 | Severe–life threatening | 5 | PEFR and admissions |
| Drobina | USA | 2006 | 110 | 12–60 | 43:67 | Mild–severe | 5 | PEFR and admissions |
| Kokturk | Turkey | 2005 | 26 | 18–60 | 73:27 | Moderate–severe | 2 | PEFR (% predicted) and admissions |
| Mahajan | USA | 2004 | 62 | 5–17 | 45:55 | Mild–moderate | 4 | FEV1 (% predicted) and admissions |
| Hughes | New Zealand | 2003 | 52 | 16–65 | 52:48 | Severe–life threatening | 5 | FEV1 and admissions |
| Bessmertny | USA | 2002 | 74 | 18–65 | 73:27 | Mild–moderate | 5 | FEV1 (% predicted) |
| Nannini | Argentina | 2000 | 35 | >18 | 63:37 | Acute exacerbation | 3 | PEFR and admissions |
| Mangat | India | 1998 | 33 | 12–60 | 70:30 | Acute exacerbation | 3 | PEFR (% predicted) and admissions |
| Meral | Turkey | 1996 | 40 | Children | Unknown | Acute asthma | 0 | PEFR (% change from baseline) and respiratory score |
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; PEFR, peak expiratory flow rate.